Media Outlets Highlight First Clinical Trial of CRISPR-Based HIV Therapy Founded on Breakthrough Research at the Lewis Katz School of Medicine

The Philadelphia Business Journal and Positively Positive: Living with HIV/AIDS highlighted news that the first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) infection is now underway, thanks to a major collaborative effort between scientists at the Lewis Katz School of Medicine at Temple University, including Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Microbiology, Immunology, and Inflammation, Director of the Center for Neurovirology and Gene Editing, and Director of the Comprehensive NeuroAIDS Center; and Tricia H. Burdo, PhD, Associate Professor in the Department of Microbiology, Immunology, and Inflammation; and investigators at Excision BioTherapeutics, Inc. The trial, designed to evaluate the safety, tolerability, and efficacy of EBT-101, marks a major step forward in the effort to find a cure for HIV/AIDS. It will take place at multiple locations, but Temple is not one of the sites.